With support from our investors, the Resitu technology has the potential to become the globally preferred method to treat breast cancer.
The Resitu technology for minimally invasive surgery is built on a patented invention by surgeon Per Hedén.
Resitu plan to launch the first product in EU and US in 2023. The first line of products will focus on biopsy and breast tissue removal
In 2021-2022 Resitu Medical raised seed capital to reach the final product design and to start series production and perform clinical trials towards CE mark and FDA clearance for our first product. Our major shareholders are Novoaim (63%), ALMI Invest Stockholm (13%) and STOAF (13%).
Series A and B rounds are planned in 2023 and 2025 to enable clinical studies, expand into additional markets and for further product development to launch the second-generation product.